-
Baekje burned 50 billion of confidence, which is the value moat in Zhang Lei's eyes
Time of Update: 2021-12-28
China economy has been through a product Zerbe imatinib, opened the cover over three billion people reporting clinical + channels, differing only in the last part of this sale, we will be able to medicines into different colors of different races in different languages of the patient one hundred The most valuable moat According to the data of Medical Rubik's Cube, Hengrui and Cinda are simultaneously compared .
-
International cooperation is a major development trend of the pharmaceutical industry
Time of Update: 2021-12-28
The rapid development of BD in recent years, on the one hand, due to the early transfer of approval documents between domestic drugs has been unable to meet the needs of enterprises, the transfer of products in more research and development stages has become a trend .
-
The ranking of chemical medicine TOP10 has changed!
Time of Update: 2021-12-28
The market share of three domestic pharmaceutical companies in public hospitals of key cities in recent years Source: Mi Nei. com's chemical drug terminal competition pattern in key cities of public hospitals From the perspective of TOP10 manufacturers, although there are only three domestic pharmaceutical companies, Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical, their market share is increasing; while foreign pharmaceutical companies occupy 7 seats, and their market shares have varying degrees.
-
Top 10 news events in the pharmaceutical industry in 2021
Time of Update: 2021-12-28
Sinopharm Zhongsheng Beijing Company and Kexing Zhongwei Company's new crown inactivated vaccines are included in the emergency use list of the World Health Organization 07.
-
Observe the similarities and differences between the system development of foreign countries and my country in the access of medicines in the medical insurance catalog
Time of Update: 2021-12-28
The biggest problem here is that some pharmaceutical manufacturers in our country will not be able to supply drugs continuously and steadily after winning the bid, leading to a shortage of drugs in the market, which can only result in the purchase of drugs at high prices on the black market .
-
For the treatment of rare diseases!
Time of Update: 2021-12-28
After many years of clinical development by Novartis, the FDA approved the new indication of ofatumumab in August 2021: as a subcutaneous injection drug for the treatment of relapsing adult patients with multiple sclerosis, including clinical isolated syndrome, relapse/remission Type disease and active secondary progressive disease .
-
Eli Lilly reaches over 1.5 billion U.S. dollars to collaborate on the development of innovative anti-cancer therapies for gene expression regulation mechanisms
Time of Update: 2021-12-28
For BRM selective inhibitors and additional undisclosed target research and development projects, Foghorn will lead drug discovery and early research activities, while Eli Lilly will be responsible for its development and commercialization activities .
com/news-releases/news-release-details/lilly-and-foghorn-announce-strategic-collaboration-novehttps://investor.
-
Pfizer acquires Arena for US$6.7 billion
Time of Update: 2021-12-28
On December 5, 2017, Genting Shining won the exclusive development and commercialization rights of etrasimod and ralinepag in Greater China from Arena, with a down payment of 12 million U.
-
Liu Jingzhen: Forging Global Competitiveness with a "Big Country" in Mind
Time of Update: 2021-12-28
Liu Jingzhen, Chairman and Party Secretary of Sinopharm Group In terms of giving full play to the production capacity advantages of production enterprises to guarantee urgent needs, the National Health Commission’s "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 7)" recommends a total of 105 varieties of drugs, and Sinopharm can independently produce 91 varieties .
-
Green Valley Pharmaceuticals abolishes the medical insurance negotiating team?
Time of Update: 2021-12-24
It is reported that China's original new drug for the treatment of Alzheimer's disease, Mannite Sodium Capsules (trade name: Nine Phase One®) has been included in the medical insurance for more than half a month.
-
Pfizer Ogaituzumab for Injection Approved in China to Treat Leukemia
Time of Update: 2021-12-24
Retrieved Dec 22, 2021, from https:// Information to be obtained for the drug approval certificate issued by the State Drug Administration of China on December 22.
-
The highest drop of 98%, Chongqing Medical Insurance Bureau announces the results of the alliance's centralized procurement
Time of Update: 2021-12-24
Experts in medical institutions have demonstrated that laparoscopic staplers and intravenous indwelling needles with sufficient competition, large price differences, and large numbers of use are included in the scope of centralized procurement .
-
FDA approves nuclide conjugate drugs for prostate cancer diagnosis!
Time of Update: 2021-12-24
TLX591-CDx is a diagnostic positron emission tomography (PET) tracer targeting prostate specific membrane antigen (PSMA) based on radionuclide-antibody coupling technology (RDC), suitable for metastatic prostate cancer And the diagnosis of recurrent prostate cancer .
-
Notice of the General Office of the Ministry of Science and Technology on Further Improving the Financial Management of Comprehensive Performance Evaluation of National Key R&D Programs
Time of Update: 2021-12-08
In accordance with the requirements of the "Opinions", in order to further improve the quality and efficiency of audits and reduce the burden on scientific researchers, the Chinese Institute of Certified Public Accountants is currently taking the lead in carrying out the revision of the "Guidelines for the Audit of the Central Financial Technology Plan Projects (Subjects)" .
-
In-depth interpretation!
Time of Update: 2021-12-08
Retrieved Feb 25, 2021, from https:// aspx[3] Tianjing Biopharmaceuticals announced that the Phase 3 registered clinical study of Etan Growth Hormone Alpha has completed the first patient administration.
-
Huahai broke out! FDA warning letter closes, wins 5 blockbuster varieties and 10 innovative drugs
Time of Update: 2021-12-08
Recently, Huahai Pharmaceuticals announced heavy news: the southern Sichuan API base warning has been lifted, and sales in the US market are expected to resume .
-
First oral drug for COVID-19 approved
Time of Update: 2021-12-08
The British Medicines and Healthcare Products Administration (MHRA) has approved Merck’s molnupiravir for the treatment of adult patients with mild to moderate COVID-19 who have a positive SARS-CoV-2 diagnostic test and have at least one risk factor for serious disease .
-
Food and Drug Administration: "Shuiguang Needle" is planned to be supervised by Class III medical devices
Time of Update: 2021-12-08
On November 9, the Medical Device Standards Management Center of the State Drug Administration issued a notice on the solicitation of the "Medical Device Classification Catalogue" (adjustment opin
-
AffaMed Therapeutics announces the establishment of a wholly-owned subsidiary, AffaMed Digital
Time of Update: 2021-12-08
AffaMed Therapeutics (hereinafter referred to as "AffaMed"), a clinical-stage innovative pharmaceutical company dedicated to meeting the global needs for the treatment of ophthalmic, neurological and psychiatric diseases, today announced the establishment of a wholly-owned subsidiary, AffaMed Digital .
-
Announcement of the Center for Drug Evaluation of the State Drug Administration on Issuing the "Technical Guidelines for the Detection of Minimal Residual Diseases in Clinical Trials of Chronic Myeloid Leukemia Drugs" (No. 43 of 2021)
Time of Update: 2021-12-08
In order to encourage the development of new anti-tumor drugs, under the deployment of the National Medical Products Administration, the Center for Drug Evaluation has organized and formulated the "Technical Guidelines for the Detection of Minimal Residual Diseases in Clinical Trials of Chronic Myeloid Leukemia Drugs" (see appendix) .
